New Delhi, Jan 17 (PTI) Strides Pharma Science Ltd on Monday said its Singapore-based arm has received approval from the US health regulator for its generic version of oseltamivir phosphate for oral suspension, used for treating illness due to influenza.

The approval granted by the US Food & Drug Administration (USFDA) to Strides Pharma Global Pte. Ltd, Singapore, is for oseltamivir phosphate for oral suspension of strength 6 mg/ml, the company said in a statement.

Also Read | Uttarakhand Assembly Elections 2022: Harak Singh Rawat Expelled From BJP as He Mounted Pressure for Party Tickets to Kin, Says Pushkar Singh Dhami.

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tamiflu for Oral Suspension, 6 mg/mL, of Hoffmann-La Roche, Inc, it added.

The product will be manufactured at the company's facility in Bengaluru and will be marketed by Strides Pharma Inc in the US market.

Also Read | India Records 2,58,089 New COVID-19 Cases, 385 Deaths; Positivity Rate at 19.65%.

Citing IQVIA MAT November 2020 data, the company said the US market for oseltamivir phosphate for oral suspension, 6 mg/mL, was about USD 132 million.

Strides has 271 cumulative abbreviated new drug application (ANDAs) filings with USFDA, of which 243 ANDAs have been approved and 28 are pending approvals. HRS hrs

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)